Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M53.8Revenue $M19.0Net Margin (%)-78.9Altman Z-Score-15.3
Enterprise Value $M29.2EPS $-0.3Operating Margin %-65.3Piotroski F-Score3
P/E(ttm)--Beneish M-Score-1.1Pre-tax Margin (%)-78.9Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %--Quick Ratio3.3Cash flow > EarningsN
Price/Sales2.85-y EBITDA Growth Rate %--Current Ratio3.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-31.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-85.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M58.2ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with AVEO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AVEOSeth Klarman 2014-12-31 Sold Out -0.07%$0.65 - $1.17
($0.91)
$ 0.921%Sold Out0
AVEOGeorge Soros 2014-09-30 Sold Out $1.09 - $1.79
($1.26)
$ 0.92-27%Sold Out0
AVEOGeorge Soros 2014-06-30 Buy $1.02 - $1.72
($1.29)
$ 0.92-29%New holding49,076
AVEOSeth Klarman 2013-06-30 Reduce-0.26%$2.34 - $8.27
($4.27)
$ 0.92-78%Reduce -21.90%3,829,350
AVEOGeorge Soros 2011-12-31 Sold Out -0.0031%$14.53 - $17.35
($8.42)
$ 0.92-89%Sold Out0
AVEOSeth Klarman 2011-09-30 Add0.29%$15.12 - $20.77
($17.66)
$ 0.92-95%Add 12.79%5,000,000
AVEOGeorge Soros 2011-09-30 Reduce-0.04%$15.12 - $20.77
($17.66)
$ 0.92-95%Reduce -92.80%11,600
AVEOSeth Klarman 2011-06-30 Add0.78%$13.06 - $20.66
($16.79)
$ 0.92-95%Add 25.76%4,433,010
AVEOGeorge Soros 2011-06-30 Buy 0.05%$13.06 - $20.66
($16.79)
$ 0.92-95%New holding161,000
AVEOSeth Klarman 2011-03-31 Add1.15%$13.15 - $15.02
($14.21)
$ 0.92-94%Add 76.25%3,525,000
AVEOSeth Klarman 2010-12-31 Buy 1.68%$13.84 - $17.41
($15.14)
$ 0.92-94%New holding2,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AVEO is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


AVEO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dallas Matthew DVP, Finance 2015-01-16Sell3,075$0.8218.29view
Gyuris JenoSVP, Chief Scientific Officer 2015-01-07Sell4,484$0.821.25view
Vittiglio JosephSVP, General Counsel 2015-01-07Sell4,484$0.821.25view
Dallas Matthew DVP, Finance 2015-01-07Sell519$0.821.25view
BAILEY MICHAEL PPresident & CEO 2015-01-07Sell4,484$0.821.25view
Dallas Matthew DVP, Finance 2014-07-01Sell0$021.25view
BAILEY MICHAEL PChief Business Officer 2014-01-30Sell5,430$1.64-40.85view
Slichenmyer WilliamChief Medical Officer 2014-01-30Sell5,430$1.64-40.85view
Gyuris JenoSVP, Chief Scientific Officer 2014-01-30Sell5,430$1.64-40.85view
Vittiglio JosephSVP, General Counsel 2014-01-30Sell5,430$1.64-40.85view

Quarterly/Annual Reports about AVEO:

    News about AVEO:

    Articles On GuruFocus.com
    Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
    Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
    Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
    Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
    Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
    AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
    Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
    Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

    More From Other Websites
    ETF’s with exposure to AVEO Pharmaceuticals, Inc. : April 19, 2016 Apr 19 2016
    ETF’s with exposure to AVEO Pharmaceuticals, Inc. : April 5, 2016 Apr 05 2016
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 04 2016
    Coverage initiated on AVEO Oncology by FBR Capital Mar 30 2016
    Aveo Pharmaceuticals to pay $4 mln to settle kidney drug case Mar 29 2016
    Feds charge Cambridge drug firm, former execs with misleading investors Mar 29 2016
    SEC Charges Aveo With Misleading Investors Mar 29 2016
    Aveo Pharmaceuticals to pay U.S. SEC $4 mln to settle kidney drug case Mar 29 2016
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events Mar 24 2016
    ETF’s with exposure to AVEO Pharmaceuticals, Inc. : March 23, 2016 Mar 23 2016
    AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 23 2016
    AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences Mar 23 2016
    AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: 2015 By the Numbers Mar 22 2016
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Mar 21 2016
    AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North... Mar 21 2016
    AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North... Mar 21 2016
    AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North... Mar 21 2016
    AVEO PHARMACEUTICALS INC Financials Mar 18 2016
    AVEO Q4 Loss Narrower than Expected, Tivozanib in Focus Mar 16 2016
    AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4 Mar 15 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)